U.S. markets open in 2 hours 42 minutes
  • S&P Futures

    3,847.50
    +38.25 (+1.00%)
     
  • Dow Futures

    31,191.00
    +279.00 (+0.90%)
     
  • Nasdaq Futures

    13,082.75
    +171.75 (+1.33%)
     
  • Russell 2000 Futures

    2,244.00
    +44.80 (+2.04%)
     
  • Crude Oil

    62.20
    +0.70 (+1.14%)
     
  • Gold

    1,740.10
    +11.30 (+0.65%)
     
  • Silver

    26.87
    +0.43 (+1.63%)
     
  • EUR/USD

    1.2044
    -0.0044 (-0.36%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    25.27
    -3.62 (-12.53%)
     
  • GBP/USD

    1.3959
    +0.0037 (+0.27%)
     
  • USD/JPY

    106.7100
    +0.2080 (+0.20%)
     
  • BTC-USD

    47,768.05
    +2,483.32 (+5.48%)
     
  • CMC Crypto 200

    960.49
    +27.36 (+2.93%)
     
  • FTSE 100

    6,570.02
    +86.59 (+1.34%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Replimune to Provide Data Update on June 3, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

WOBURN, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host a conference call to provide updated data from patients with melanoma and non-melanoma skin cancers treated with RP1 combined with Opdivo® in its ongoing Phase 1/2 clinical trial. The investor event will be held on June 3, 2020. The Company will not be presenting data at the ASCO Annual Meeting this year, which has transitioned to a virtual format. The Company will provide additional details on the event at a later date.

About Replimune

Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic immune-gene therapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
agoldenberg@vergescientific.com